<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53705">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407028</url>
  </required_header>
  <id_info>
    <org_study_id>GLR-NIH-2015</org_study_id>
    <nct_id>NCT02407028</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Brain Injury Treatment Trial</brief_title>
  <acronym>HOBIT</acronym>
  <official_title>Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gaylan Rockswold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this innovative adaptive phase II trial design is to determine the optimal
      hyperbaric oxygen (HBO2) treatment paradigm to be instituted in terms of atmospheric
      pressure, frequency of treatment and whether normobaric hyperoxia (NBH) following HBO2
      treatments enhances the treatment effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical and clinical investigations strongly indicate that HBO2 is physiologically
      active in improving the destructive processes in severe Traumatic Brain Injury (TBI).
      However, prior to a definitive efficacy study, important information is required regarding
      optimizing the HBO2 treatment paradigm instituted in terms of pressure, frequency and
      whether NBH enhances the clinical effectiveness of the HBO2 treatment. Preclinical
      investigators working with TBI models have used pressures varying from 1.5 to 3.0
      atmospheres absolute (ATA). Clinical investigators have used pressure varying from 1.5 to
      2.5 ATA. However, the lungs in severe TBI patients have frequently been compromised by
      direct lung injury and/or acquired ventilator pneumonia and are susceptible to oxygen (O2)
      toxicity. Working within these constraints, it is essential to determine the most effective
      HBO2 dose schedule without producing O2 toxicity and clinical complications. This proposed
      clinical trial is designed to answer these questions and to provide important data to plan a
      definitive efficacy trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Outcome Score (GOS)</measure>
    <time_frame>Assessment at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glasgow Outcome Score (GOS)</measure>
    <time_frame>Assessment at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes- Disability rating scale</measure>
    <time_frame>Assessment at 3 months</time_frame>
    <description>Disability rating scale (DRS, 28 day survival, ventilator, ICU and hospital free days, incidence of severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes- Disability rating scale</measure>
    <time_frame>Assessment at 6 months</time_frame>
    <description>Disability rating scale (DRS, 28 day survival, ventilator, ICU and hospital free</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Brain Injuries</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Oxygen utilizing HBO with variations of pressure, frequency, and NBH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated with usual and customary care for traumatic brain injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.0 ATA, no NBH everyday X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.5 ATA, no NBH everyday X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 1.5 ATA, with NBH everyday X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.0 ATA, with NBH everyday X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.5 ATA, with NBH everyday X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 1.5 ATA, no NBH twice per day X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.0 ATA, no NBH twice per day X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 2.5 ATA, no NBH twice per day X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>HBO Oxygen; 1.5 ATA, with NBH twice per day X five days or until patient following commands or brain dead</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual and customary care for severe traumatic brain injury</intervention_name>
    <description>Will be treated with usual and customary care for severe traumatic brain injury</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Standard Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GCS score less than or equal to 6 or GCS score 7 or 8 and Marshall CT score &gt; 3

          -  Patients not requiring craniotomy or major surgical procedures will be enrolled and
             HBO2 treatment initiated within 6 hours of admission.

          -  Patients requiring a craniotomy or major surgical procedure will be enrolled and HBO2
             treatment initiated within 12 hours.

          -  Informed consent obtained

          -  Blunt mechanism only

        Exclusion Criteria:

          -  GCS 3 AND bilaterally unreactive pupils &gt; 4 mm

          -  Severe pre-existing neurological deficits, e.g., previous TBI, stroke

          -  Acute spinal cord injury

          -  Fixed coagulopathy. INR &gt; 1.4 despite correction attempts

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaylan L Rockswold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaylan L. Rockswold, MD</last_name>
    <phone>612-873-2810</phone>
    <email>gaylan.rockswold@hcmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tami Hauff</last_name>
    <phone>612-873-2810</phone>
    <email>tami.hauff@hcmed.org</email>
  </overall_contact_backup>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Minneapolis Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Gaylan Rockswold</investigator_full_name>
    <investigator_title>M.D., Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
